Last reviewed 2026-04-23 · How we verify

IV titration of morphine chlorhydrate

University Hospital, Rouen · Phase 3 active Small molecule

IV titration of morphine chlorhydrate is a Opioid analgesic Small molecule drug developed by University Hospital, Rouen. It is currently in Phase 3 development for Acute severe pain in hospitalized patients, Postoperative pain management. Also known as: Inhaled placebo.

Morphine binds to opioid receptors in the central nervous system to produce analgesia and sedation through inhibition of pain signal transmission.

Morphine binds to opioid receptors in the central nervous system to produce analgesia and sedation through inhibition of pain signal transmission. Used for Acute severe pain in hospitalized patients, Postoperative pain management.

Likelihood of approval

58.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	IV titration of morphine chlorhydrate
Also known as	Inhaled placebo
Sponsor	University Hospital, Rouen
Drug class	Opioid analgesic
Target	Mu-opioid receptor (μ-OR)
Modality	Small molecule
Therapeutic area	Pain Management
Phase	Phase 3

Mechanism of action

Morphine is a mu-opioid receptor agonist that crosses the blood-brain barrier and acts on opioid receptors in the spinal cord and brain to modulate pain perception and emotional response to pain. IV titration allows for rapid onset and precise dose adjustment to achieve desired analgesia while minimizing overdose risk. This formulation is commonly used for acute severe pain management in hospital settings.

Approved indications

Acute severe pain in hospitalized patients
Postoperative pain management

Common side effects

Respiratory depression
Hypotension
Nausea and vomiting
Sedation
Constipation
Pruritus

Key clinical trials

Inhaled vs IV Opioid Dosing for the Initial Treatment of Severe Acute Pain in the Emergency Department (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

IV titration of morphine chlorhydrate CI brief — competitive landscape report
IV titration of morphine chlorhydrate updates RSS · CI watch RSS
University Hospital, Rouen portfolio CI

Frequently asked questions about IV titration of morphine chlorhydrate

What is IV titration of morphine chlorhydrate?

IV titration of morphine chlorhydrate is a Opioid analgesic drug developed by University Hospital, Rouen, indicated for Acute severe pain in hospitalized patients, Postoperative pain management.

How does IV titration of morphine chlorhydrate work?

Morphine binds to opioid receptors in the central nervous system to produce analgesia and sedation through inhibition of pain signal transmission.

What is IV titration of morphine chlorhydrate used for?

IV titration of morphine chlorhydrate is indicated for Acute severe pain in hospitalized patients, Postoperative pain management.

Who makes IV titration of morphine chlorhydrate?

IV titration of morphine chlorhydrate is developed by University Hospital, Rouen (see full University Hospital, Rouen pipeline at /company/university-hospital-rouen).

Is IV titration of morphine chlorhydrate also known as anything else?

IV titration of morphine chlorhydrate is also known as Inhaled placebo.

What drug class is IV titration of morphine chlorhydrate in?

IV titration of morphine chlorhydrate belongs to the Opioid analgesic class. See all Opioid analgesic drugs at /class/opioid-analgesic.

What development phase is IV titration of morphine chlorhydrate in?

IV titration of morphine chlorhydrate is in Phase 3.

What are the side effects of IV titration of morphine chlorhydrate?

Common side effects of IV titration of morphine chlorhydrate include Respiratory depression, Hypotension, Nausea and vomiting, Sedation, Constipation, Pruritus.

What does IV titration of morphine chlorhydrate target?

IV titration of morphine chlorhydrate targets Mu-opioid receptor (μ-OR) and is a Opioid analgesic.

Drug class: All Opioid analgesic drugs
Target: All drugs targeting Mu-opioid receptor (μ-OR)
Manufacturer: University Hospital, Rouen — full pipeline
Therapeutic area: All drugs in Pain Management
Indication: Drugs for Acute severe pain in hospitalized patients
Indication: Drugs for Postoperative pain management
Also known as: Inhaled placebo